Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
YPL-001 in Moderate-to-Severe COPD
NCT02272634Phase 2Completed
- Sponsor
- Yungjin Pharm. Co., Ltd.
- Start
- Jun 2015
- Primary completion
- Nov 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of YPL-001 in chronic obstructive pulmonary disease (COPD) (3 arms), sponsored by Yungjin Pharm. Co., Ltd. Primary endpoint: Treatment-Emergent Adverse Event Frequency at Day 56. Started Jun 2015; status: completed.
02
Drugs
YPL-001
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT02272634.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02272634.